## IN THE CLAIMS:

The following listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims

## 1 - 21 (Canceled)

22. (New) A method of inhibiting apoptosis in a patient for the treatment of prion diseases which comprises administering an effective amount of a compound of formula (I):

$$N^{-}CH_{2}^{-}C^{-}Z$$

$$Z'' Z'$$
(1)

in which:

- R<sub>1</sub> represents a halogen or a CF<sub>3</sub>, (C<sub>1</sub>-C<sub>4</sub>)alkyl or (C<sub>1</sub>-C<sub>4</sub>)alkoxy group;
- Y represents a nitrogen atom [or a CH group];
- Z' and Z" each represent hydrogen or a (C1-C3) alkyl group, or one represents hydrogen and the other a hydroxy group, or both, together, represent an oxo group;
- Z represents

## a phenyl radical;

a phenyl radical monosubstituted with a substituent X, X being

- (C<sub>1</sub>-C<sub>6</sub>)alkoxy; (C<sub>3</sub>-C<sub>7</sub>)carboxyalkyl; a) a  $(C_1-C_6)$ alkyi;  $C_4$ )alkoxycarbonyl( $C_1$ - $C_6$ )alkyl; ( $C_3$ - $C_7$ )carboxyalkoxy or ( $C_1$ - $C_4$ )alkoxycarbonyl(C<sub>1</sub>-C<sub>6</sub>)alkoxy group;
- b) a group selected from a (C3-C7)cycloalkyl, (C3-C7)cycloalkyloxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl group, it being possible for said group to be substituted with a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino, mono- or di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino;

- c) a group selected from a phenyl, phenoxy, phenylamino, N-(C1-C3) alkylphenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl or styryl, it being possible for said group to be mono- or poly-substituted on the phenyl group with a halogen, CF3, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or (C<sub>1</sub>-C<sub>4</sub>)acylamino, carboxy, (C<sub>1</sub>di-(C1-C4)alkylamino, di-(C1aminocarbonyl, C4)alkoxycarbonyl, mono-OT C<sub>4</sub>)alkylaminocarbonyl, amino(C<sub>1</sub>-C<sub>4</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyl or  $halo(C_1-C_4)alkyl;$
- a phenyl radical disubstituted with a substituent R<sub>2</sub>, R<sub>2</sub> being a halogen or a hydroxy, methyl, ethyl, (C<sub>3</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy or trifluoromethyl group and with a substituent X, X being as defined above;
- a 1-naphthyl or 2-naphthyl radical;
- a 1-naphthyl or 2-naphthyl radical substituted in positions 5, 6, 7 and/or 8 with one or two hydroxyl groups, one or two (C<sub>1</sub>-C<sub>4</sub>)alkoxy groups or a 6,7-methylenedioxy group;
  - or Z' is hydrogen and Z and Z' represent, each independently, a non-substituted or mono-, di- or tri-substituted phenyl group;

or of one of its pharmaceutically acceptable salts and solvates.

Respectfully submitted,

Karen I. Krupen, Reg. No. 34,647

Attorney for Applicant

sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800

Telephone: 908-231-4658 Telefax: 908-231-2626

Docket No. IVD1000 US DIV 1